ORCHESTRA BIOMED HOLDINGS INC (OBIO)
Health Care · Cardiovascular medical devices and bioelectronic therapies · NASDAQ
Orchestra BioMed develops late-stage bioelectronic and interventional cardiovascular therapies through risk-sharing partnerships with major device makers, focused on hypertension and coronary artery disease.
What ORCHESTRA BIOMED HOLDINGS INC does
Orchestra BioMed is a biomedical innovation company developing late-stage clinical medical device candidates through strategic partnerships with market-leading device manufacturers. The company's flagship programs are AVIM Therapy, a bioelectronic treatment for hypertension integrated into cardiac pacemakers (in collaboration with Medtronic), and Virtue Sirolimus AngioInfusion Balloon, a drug-coated balloon for coronary artery disease. The company operates under a risk-reward-sharing partnership model with major medical device companies.
Themes: ["bioelectronic therapy / cardiac devices","hypertension treatment","coronary artery disease / restenosis","drug-coated balloons","pacemaker technology","medical device partnerships"]
Fundamentals
- Price$3.92 as of 2026-07-09 close
- Market cap$235M as of 2026-07-10
- 1-year return+33.8% as of 2026-07-09 close
- Net margin-166.8% as of 2026-07-10
- Gross margin+99.5% as of 2026-07-10
- ROE-137.8% as of 2026-07-10
- Debt / equity0.28 as of 2026-07-10
- Revenue growth (YoY)+1033.9% as of 2026-07-10
- Revenue CAGR (3y)+111.6% SEC XBRL
- Beta0.51 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: BACKBEAT study enrollment targeted for mid-2026 with 500 patients; Virtue SAB trial enrollment targeted through mid-2027 with 740 patients; failure to enroll or achieve efficacy endpoints could derail both flagship programs","Dependence on strategic partnerships: exclusive collaboration with Medtronic for AVIM Therapy and comparison against Boston Scientific's AGENT balloon for Virtue SAB; partners control commercialization timelines and market access","Significant operating losses and cash burn: net margin of -166.75%, cumulative accumulated deficit of $383.3 million as of March 2026, with cash and equivalents of $28.4 million; company will require additional capital to fund ongoing clinical trials"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.